Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.

Literature DB >> 6173545

Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.

G E Rivard, R L Momparler, J Demers, P Benoit, R Raymond, K Lin, L F Momparler.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1981 PMID： 6173545 DOI： 10.1016/0145-2126(81)90116-8

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

Keyword Cloud
Cited

× No keyword cloud information.

39 in total

1. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.

Authors: J Laliberté; V E Marquez; R L Momparler
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333

Review 2. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors: Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal: Semin Oncol Date: 2012-02 Impact factor: 4.929

Review 3. Epigenetic therapy of leukemia: An update.

Authors: Nitin Jain; Adriana Rossi; Guillermo Garcia-Manero
Journal: Int J Biochem Cell Biol Date: 2008-10-17 Impact factor: 5.085

4. UBC and YWHAZ as suitable reference genes for accurate normalisation of gene expression using MCF7, HCT116 and HepG2 cell lines.

Authors: Siang Ling Chua; Wei Cun See Too; Boon Yin Khoo; Ling Ling Few
Journal: Cytotechnology Date: 2011-08-18 Impact factor: 2.058

Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.

1. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.

Review 2. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Review 3. Epigenetic therapy of leukemia: An update.

4. UBC and YWHAZ as suitable reference genes for accurate normalisation of gene expression using MCF7, HCT116 and HepG2 cell lines.

5. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.

6. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.

7. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.

8. [Development of the risk of infection in the child with leukemia].

Review 9. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

10. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.